Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc.

NNASDAQ:KLRS
1.46
USD
-0.11
(-7.30%)
-1.84EPS
68.80MMarket Cap
Mar 23Next Earn

Total Valuation

USD

As of September 30, 2026, Kalaris Therapeutics, Inc. carries a market capitalization of 68.80M, placing it among publicly traded companies globally. Its enterprise value stands at -12.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap68.80M
Enterprise Value-12.73M

Important Dates

Kalaris Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 23, 2027.

Earnings Date3/23/2027

Share Statistics

As of September 30, 2026, Kalaris Therapeutics, Inc. has 23.80M shares outstanding.

Shares Outstanding23.80M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio1.45
P/TBV Ratio1.45
P/FCF Ratio-1.69
P/OCF Ratio-1.69

Financial Position

As of September 30, 2026, Kalaris Therapeutics, Inc. maintains a current ratio of 10.00, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities.

Current Ratio10.00
Quick Ratio9.73
Debt / Equity2.81
Debt / EBITDA-0.03

Financial Efficiency

Over the twelve months ended September 30, 2026, Kalaris Therapeutics, Inc. posted a negative return on equity (ROE) of -97.23, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -51.00, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 20.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-97.23
Return on Assets (ROA)-51.00
Employee Count20.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Kalaris Therapeutics, Inc.'s stock has declined approximately 73.26% over the past 52 weeks. The 50-day moving average sits at 2.49, while the 200-day moving average is 4.99.

52-Week Price Change-73.26%
50-Day Moving Average2.49
200-Day Moving Average4.99

Income Statement

USD

Over the twelve months ended September 30, 2026, Kalaris Therapeutics, Inc. generated - - in revenue and converted that into -43.39M in net income, yielding earnings per share of -1.84. EBITDA reached -46.79M, while operating income came in at -46.83M.

Operating Income-46.83M
Pretax Income-43.39M
Net Income-43.39M
EBITDA-46.79M
EBIT-46.83M
Earnings Per Share (EPS)-1.84

Balance Sheet

USD

As of September 30, 2026, Kalaris Therapeutics, Inc. holds 82.86M in cash and equivalents against 1.33M in total debt, resulting in a net debt position of -47.38M. Total book value stands at 47.40M, with working capital of 76.66M providing operational flexibility.

Cash & Cash Equivalents82.86M
Total Debt1.33M
Net Debt-47.38M
Equity (Book Value)47.40M
Book Value Per Share1.99
Working Capital76.66M

Cash Flow

USD

Kalaris Therapeutics, Inc. produced -40.24M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -17,000.00 in capital expenditures, free cash flow totaled -40.26M - equivalent to -1.71 per share.

Operating Cash Flow-40.24M
Capital Expenditures-17,000.00
Free Cash Flow-40.26M
FCF Per Share-1.71

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -59.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -66.27, meaning Kalaris Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-66.27
FCF Yield-59.13

Stock Splits

Kalaris Therapeutics, Inc.'s most recent stock split took place on January 16, 2025 with a 23:1 split ratio.

Last Split Date1/16/2025
Split Ratio23:1

Scores

As of September 30, 2026, Kalaris Therapeutics, Inc. has an Altman Z-Score of -2.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.75